Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ovid Therapeutics Inc.

1.63
+0.07004.49%
Post-market: 1.61-0.0200-1.23%19:55 EDT
Volume:1.43M
Turnover:2.31M
Market Cap:115.91M
PE:-3.04
High:1.65
Open:1.56
Low:1.56
Close:1.56
52wk High:2.01
52wk Low:0.2425
Shares:71.11M
Float Shares:59.52M
Volume Ratio:0.99
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5359
EPS(LYR):-0.3663
ROE:-52.77%
ROA:-26.71%
PB:2.08
PE(LYR):-4.45

Loading ...

Oppenheimer upgrades Ovid Therapeutics (OVID) to a Buy

TIPRANKS
·
Oct 09

William Blair Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Oct 04

BUZZ-U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet

Reuters
·
Oct 03

Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Another Interest Rate Cut for 2025

MT Newswires Live
·
Oct 03

Ovid Therapeutics Agrees to Financing Deal Worth up to $175 million

MT Newswires Live
·
Oct 03

BUZZ-Ovid Therapeutics jumps after seizure treatment shows promise in trial

Reuters
·
Oct 03

Ovid Shares Leap Premarket on Positive Study Results, Financing Pact

Dow Jones
·
Oct 03

Top Premarket Gainers

MT Newswires Live
·
Oct 03

Ovid Therapeutics Shares up 25.6% Premarket After Co Reports Early-Stage Data for Seizure Treatment

THOMSON REUTERS
·
Oct 03

Ovid Therapeutics prices private placement up to $175M in gross proceeds

TIPRANKS
·
Oct 03

Ovid Therapeutics Announces $175 Million Private Placement to Fund Pipeline Through 2028

Reuters
·
Oct 03

Ovid Therapeutics Announces Positive Phase 1 Results for OV329, Plans Phase 2a Trial for Drug-Resistant Focal Onset Seizures in 2026

Reuters
·
Oct 03

Ovid Therapeutics Inc - Ov329 Safety Results Preferable to Marketed Asms

THOMSON REUTERS
·
Oct 03

Ovid Therapeutics Inc - Ov329 Matched or Exceeded Vigabatrin Inhibition on Tms

THOMSON REUTERS
·
Oct 03

Ovid Announces Positive Topline Results for the Next-Generation Gaba-Aminotransferase Inhibitor, Ov329, That Demonstrate Strong Inhibitory Activity and a Potential Best-in-Category Safety Profile

THOMSON REUTERS
·
Oct 03

Ovid Therapeutics - Regains Compliance With Nasdaq Listing Rule - SEC Filing

THOMSON REUTERS
·
Sep 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 15

Ovid Therapeutics Inc. Unveils Presentation on Innovative Neurotherapeutics Pipeline Targeting Neural Hyperexcitability Conditions

Reuters
·
Aug 15

Ovid Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Ovid Therapeutics Q2 2025: Revenues Surge to $6.3M, Net Loss of $4.7M, EPS at -$0.06

Reuters
·
Aug 13